Looking for stocks for the long term? You might want to consider buying this artificial intelligence stock, diabetes stock, and dividend-paying utility stock.
News & Analysis: Insulet
The market has been pumped up about shares of the leader in tubeless insulin pump technology, which have more than doubled in 2019.
In the second quarter, the diabetes management specialist's earnings flipped to positive and it raised its full-year 2019 revenue guidance.
The insulin pump maker's second-quarter financial results are sparking optimism.
PODD earnings call for the period ending June 30, 2019.
These three medtech companies are at the forefront of diabetes care.
Shares of the leader in tubeless insulin pump technology continued their upward climb last month.
Medical devices can be ultra reliable, lucrative business, but there are plenty of ways for companies to blow it, too.
In the first quarter, the tubeless insulin pump specialist's revenue growth accelerated and it raised its full-year 2019 guidance.
The insulin pump maker reported better-than-expected first-quarter financials and issued a rosier outlook for 2019.